Drugs #
Two questions about the world's medicines: what they earn, and what regulators have just decided about them. Nothing here is medical advice or a recommendation to buy or sell a share. Spotted a wrong number?
Where to go #
Top drugs by revenue
337 medicines ranked on what the companies selling them actually reported over the most recent four quarters, in euros, each with its quarterly history. Quarterly series 2010Q1-2026Q2.
Approvals and EU decisions
1647 FDA approvals, biologics licences and EU regulatory decisions over 5 years, filterable by company size, regulator and decision type, plus the 21 medicines currently waiting on Brussels.
Immunology and inflammation
29 autoimmune and inflammation molecules across 21 target mechanisms, 20 of them approved, with the trailing-year revenue of the ones that sell. Filter by mechanism, indication, route or sponsor to see where the field is crowded.
Best sellers #
The ten medicines earning the most, on the four most recent quarters their makers reported, converted to euros. Trailing year to 2026Q2. See all 337 ranked.
| # | Medicine | Company | Revenue | Change |
|---|---|---|---|---|
| 1 | Mounjaro | Eli Lilly | EUR 27.9bn | +94% |
| 2 | Keytruda | Merck | EUR 27.7bn | -1% |
| 3 | Dupixent | Sanofi | EUR 17.7bn | +24% |
| 4 | Skyrizi | AbbVie | EUR 16.9bn | +24% |
| 5 | Ozempic | Novo Nordisk | EUR 16.3bn | -5% |
| 6 | Zepbound | Eli Lilly | EUR 14.5bn | +79% |
| 7 | Eliquis | BMS + Pfizer | EUR 13.6bn | +10% |
| 8 | Darzalex | J&J | EUR 13.5bn | +14% |
| 9 | Biktarvy | Gilead | EUR 12.7bn | -1% |
| 10 | Wegovy | Novo Nordisk | EUR 10.7bn | +8% |
Recent decisions #
New medicines and EU marketing authorisations, newest first. Label extensions on medicines already approved are left out, because there are far more of them and they would bury the rest. A further 21 medicines have cleared Europe's scientific committee and are waiting on a decision from Brussels, the longest for 479 days. All 1647 decisions, or the 21 waiting.
| Date | Decision | Medicine | Substance | Company |
|---|---|---|---|---|
| 2026-08-28 | FDA New medicine | Mimrylo | rusfertide | Takeda |
| 2026-08-20 | EU Authorisation | Aujemflu | Influenza vaccine | CSL |
| 2026-08-19 | FDA New medicine | Pasatru | garetosmab-grts | Regeneron |
| 2026-08-13 | FDA New medicine | Zenbexus | iberdomide | BMS |
| 2026-08-05 | FDA New medicine | Orzeyful | oveporexton | Takeda |
| 2026-07-24 | FDA New medicine | Simtriyo | centanafadine | Otsuka |